Related references
Note: Only part of the references are listed.Discovery of a highly selective JAK3 inhibitor for the treatment of rheumatoid arthritis
Heying Pei et al.
SCIENTIFIC REPORTS (2018)
The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond
Nicolo Costantino Brembilla et al.
FRONTIERS IN IMMUNOLOGY (2018)
Small molecule therapy for managing moderate to severe psoriatic arthritis
Luisa Costa et al.
EXPERT OPINION ON PHARMACOTHERAPY (2017)
The role of IL-23 and the IL-23/TH17 immune axis in the pathogenesis and treatment of psoriasis
G. Girolomoni et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)
Whole-cell cholera vaccines provide little protection to children
[Anonymous]
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2017)
TNF-α in a molecularly targeted therapy of psoriasis and psoriatic arthritis
Dominika Wcislo-Dziadecka et al.
POSTGRADUATE MEDICAL JOURNAL (2016)
IL-12 protects from psoriasiform skin inflammation
Paulina Kulig et al.
NATURE COMMUNICATIONS (2016)
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials
K. A. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
Christopher E. M. Griffiths et al.
LANCET (2015)
Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial
Herve Bachelez et al.
LANCET (2015)
Etiology and Pathogenesis of Psoriasis
Wolf-Henning Boehncke
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA (2015)
Effects of tofacitinib on lymphocyte sub-populations, CMV and EBV viral load in patients with plaque psoriasis
Fernando Valenzuela et al.
BMC DERMATOLOGY (2015)
The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells
Satoshi Kubo et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Fate of Lymphocytes after Withdrawal of Tofacitinib Treatment
Elisa Piscianz et al.
PLOS ONE (2014)
Targeting the IL-12/IL-23 axis An alternative approach to removing tumor induced immune suppression
Mark J. Smyth et al.
ONCOIMMUNOLOGY (2014)
Janus kinase inhibitors in autoimmune diseases
John J. O'Shea et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment
B. Strober et al.
BRITISH JOURNAL OF DERMATOLOGY (2013)
Clinical utility of the oral JAK inhibitor tofacitinib in the treatment of rheumatoid arthritis
Maurizio Cutolo et al.
JOURNAL OF INFLAMMATION RESEARCH (2013)
The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cells
Keisuke Maeshima et al.
ARTHRITIS AND RHEUMATISM (2012)
Inhibition of JAKs in Macrophages Increases Lipopolysaccharide-Induced Cytokine Production by Blocking IL-10-Mediated Feedback
Michael J. Pattison et al.
JOURNAL OF IMMUNOLOGY (2012)
Cytokine release from innate immune cells: association with diverse membrane trafficking pathways
Paige Lacy et al.
BLOOD (2011)
Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)
Kamran Ghoreschi et al.
JOURNAL OF IMMUNOLOGY (2011)
Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis
Debra M. Meyer et al.
JOURNAL OF INFLAMMATION-LONDON (2010)
JAK3 Inhibition Significantly Attenuates Psoriasiform Skin Inflammation in CD18 Mutant PL/J Mice
Betty Y. Chang et al.
JOURNAL OF IMMUNOLOGY (2009)
Mechanisms of Disease: Psoriasis.
Frank O. Nestle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
LPS/TLR4 signal transduction pathway
Yong-Chen Lu et al.
CYTOKINE (2008)
The JAK-STAT signaling pathway: Input and output intergration
Peter J. Murray
JOURNAL OF IMMUNOLOGY (2007)
Share Paper
